Clinical Trial News and Research

RSS

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

Salinas Valley Memorial participates in trial of AngelMed Guardian System in high-risk heart patients

Imagine a day when you could be alerted to your impending heart attack before it happens. Research that got underway today at Salinas Valley Memorial Healthcare System could help that become a reality someday.

26 Aug 2010

Vitamin D may be effective in preventing allergies in patients cystic fibrosis, asthma

Vitamin D may be an effective therapy to treat and even prevent allergy to a common mold that can cause severe complications for patients with cystic fibrosis and asthma.

26 Aug 2010

Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines

Nabi Biopharmaceuticals announced the receipt of a patent for treating and preventing nicotine addiction with NicVAX® and related nicotine conjugate vaccines. The United States Patent and Trademark office issued U.S. Patent No. 7,776,620 entitled "Hapten-carrier conjugates for treating and preventing nicotine addiction" for the exclusive use of methods for treating and preventing nicotine addiction with NicVAX and related nicotine vaccines. This patent runs through December 2018.

26 Aug 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Plantain and broccoli fiber help in Crohn’s disease: Study

New research suggests that plant fibers in plantains and broccoli can help prevent relapses of Crohn's disease. This disease is a long term disease of the gut that is characterized by inflammation of the lining of the digestive system, with symptoms including diarrhea and abdominal pain. Crohn's disease affects between 400,000 and 600,000 people in North America. Scientists believe that rise in processed food and decrease in fibers in diet could be a reason for rise of incidence of this disease.

25 Aug 2010

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m. at The Chemical Heritage Foundation, 315 Chestnut Street, Philadelphia. The event marks the 50th anniversary of the discovery of the first genetic abnormality associated with cancer, and the first to lead to a targeted therapy for cancer.

25 Aug 2010

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

25 Aug 2010

Guided Therapeutics receives fund to commercialize LightTouch for cervical cancer detection

Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.

25 Aug 2010

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

ZymoGenetics, Inc. today announced enrollment has been completed in the Phase 2b clinical trial with PEG-Interferon lambda and ribavirin in chronic hepatitis C virus (HCV) infection.

25 Aug 2010

Insuring your health: Health law requires continued coverage for patients in clinical trials

In her latest Kaiser Health News consumer column, Michelle Andrews writes: "When Richard Crusoe was diagnosed with a rare form of soft tissue cancer called liposarcoma, the retired firefighter and his family pinned their hopes of slowing the cancer's advance on a drug that was being tested in a clinical trial" (Andrews, 8/24).

25 Aug 2010

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

To their deep dismay, researchers at Mayo Clinic discovered several years ago that laboratory samples of anaplastic thyroid cancer (ATC) they were using to help them find new treatments for this lethal disease were probably some other kind of cancer. It quickly became evident that the situation in their lab was common throughout the world. Up to half of the cell lines that were supposed to originate from patients with this rare thyroid cancer were either colon or melanoma cancer.

25 Aug 2010

Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

Kamada, Ltd., a biopharmaceutical company engaged in development, production and marketing of specialty life-saving therapeutics and Baxter International Inc., a global, diversified healthcare company announced today that they have entered into an exclusive distribution and manufacturing agreement for Kamada's liquid, ready to use, intravenous Alpha-1 Antitrypsin Product for the treatment of hereditary Alpha-1 Antitrypsin Deficiency approved by the USFDA on July 1st, 2010 for marketing under the trade name "Glassia™".

From Baxter International Inc. 25 Aug 2010

Some health overhaul policies good for consumers, bad for brokers

As changes mandated by the health law continue to emerge, news outlets are exploring how the measure will alter the landscape for consumers and for insurance professionals.

25 Aug 2010

SureGene collaborates with Medco Health Solutions to conduct REST study

SureGene, LLC and the Medco Research Institute, LLC, a wholly-owned subsidiary of Medco Health Solutions, Inc., today announced that they have entered into a novel investigative research collaboration to evaluate whether variation in genetic biomarkers previously identified by SureGene can help predict drug response for widely prescribed antipsychotic drugs in patients with serious mental illness.

25 Aug 2010

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

25 Aug 2010

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced plans to seek additional government funding for development of its novel, once-daily antibiotic, Restanza.

25 Aug 2010

BioPharm Systems enters Inc. magazine's list of fastest-growing private companies in U.S

BioPharm Systems, a leading provider of clinical trial, data, and safety solutions, today announced that it has been named to Inc. magazine's list of the fastest-growing private companies in the United States for 2010. The Inc. 500|5000 ranks companies by overall revenue growth over a three-year period. BioPharm Systems was recognized for its 60 percent three-year growth rate.

25 Aug 2010

Echo Therapeutics completes clinical study of Prelude SkinPrep System

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced the completion of a clinical study of Prelude.

25 Aug 2010

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies.

24 Aug 2010

Clinical Trial News and Research

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Salinas Valley Memorial participates in trial of AngelMed Guardian System in high-risk heart patients

Vitamin D may be effective in preventing allergies in patients cystic fibrosis, asthma

Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Plantain and broccoli fiber help in Crohn’s disease: Study

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Guided Therapeutics receives fund to commercialize LightTouch for cervical cancer detection

ZymoGenetics completes enrollment in Phase 2b PEG-IFN lambda clinical trial

Insuring your health: Health law requires continued coverage for patients in clinical trials

Mayo researchers develop new laboratory cell lines to study anaplastic thyroid cancer

Kamada, Baxter enter distribution and manufacturing agreement for Glassia Alpha-1 Antitrypsin Product

Some health overhaul policies good for consumers, bad for brokers

SureGene collaborates with Medco Health Solutions to conduct REST study

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

BioPharm Systems enters Inc. magazine's list of fastest-growing private companies in U.S

Echo Therapeutics completes clinical study of Prelude SkinPrep System

First patient treated in Synta Pharmaceuticals' clinical trial of STA-9090

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery